References
- Dutton JJ. Optic nerve sheath meningiomas. Surv. Ophthalmol.37(3), 167–183 (1992).
- Miller NR. New concepts in the diagnosis and management of optic nerve sheath meningiomas. The fifth Hoyt lecture. J. Neuroophthalmol.26(3), 200–208 (2006).
- Eddleman CS, Liu JK. Optic nerve sheath meningioma: current diagnosis and treatment. Neurosurg. Focus23(5), E4 (2007).
- Lee HBH, Garrity JA, Cameron JD, Strianese D, Bonavolonta G, Patrinely JR. Primary optic nerve sheath meningioma in children. Surv. Ophthalmol.53(6), 543–558 (2008).
- Bosch MM, Wichmann WW, Bolthauser E, Landau K. Optic nerve sheath meningiomas in patients with neurofibromatosis type 2. Arch. Ophthalmol.124(3), 379–385 (2006).
- Mafee MF, Naheedy JH. Imaging diagnosis of the optic nerve sheath meningioma. In: Primary Optic Nerve Sheath Meningioma. Jeremic B, Pitz S (Eds). Springer-Verlag, Berlin, Germany, 39–53 (2008).
- Saeed P, Tanck MWT, Freling N, Baldeschi L, Mourits MP, Bennink RJ. Somatostatin receptor scintigraphy for optic nerve sheath meningiomas. Ophthalmology116(8), 1581–1586 (2009).
- American Joint Committee on Cancer. Cancer Staging Manual. Springer, NY, USA, 593–597 (2010).
- Hanemann CO. Magic but treatable? Tumors due to loss of Merlin. Brain131(4), 606–615 (2008).
- Yohay KH. The genetic and molecular pathogenesis of NF1 and NF2. Semin. Pediatr. Neurol.13(1), 21–26 (2006).
- Striedinger K, Van den Berg SR, Baia GS, McDermott MW, Gutmann DH, Lal A. The neurofibromatosis 2 tumor suppressor gene product, Merlin, regulates human meningioma cell growth by signaling through YAP. Neoplasia10(11), 1204–1212 (2008).
- Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell. Biol.177(5), 893–903 (2007).
- Houshmandi SS, Emnett RJ, Giovanni M, Gutmann DH. The neurofibromatosis 2 protein, Merlin, regulates glial cell growth in an ErbB2- and Src-dependent manner. Mol. Cell. Biol.29(6), 1472–1486 (2009).
- Chang Z, Guo C-L, Ahronowitz I, Stemmer-Rachamimow AO, MacCollin M, Nunes FP. A role for the p53 pathway in the pathology of meningiomas with NF2 loss. J. Neurooncol.91(3), 265–270 (2009).
- Roser F, Nakamura M, Martini-Thomas R, Samii M, Tatagiba M. The role of surgery in meningiomas involving the optic nerve sheath. Clin. Neurol. Neurosurg.108(4), 470–476 (2006).
- Turbin RE, Wladis EJ, Frohman LP, Langer PD, Kennerdell JS. Role for surgery as adjuvant therapy in optic nerve sheath meningioma. Ophthal. Plast. Reconstr. Surg.22(4), 278–282 (2006).
- Stieber VW. Radiation therapy for visual pathway tumors. J. Neuroophthalmol.28(3), 222–230 (2008).
- Jeremic B, Pitz S. Primary optic nerve sheath meningioma. Stereotactic fractioned radiaton therapy as an emerging treatment of choice. Cancer110(4), 714–722 (2007).
- Milker-Zabel M, Huber P, Schlegel W, Debus J, Zabel-du Bois A. Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningioma. J. Neurooncol.94(4), 419–424 (2009).
- Richards JC, Roden D, Harper CS. Management of sight-threatening optic nerve sheath meningioma with fractionated stereotactic radiotherapy. Clin. Exp. Ophthalmol.33(1), 137–141 (2005).
- Saeed P, Blank L, Selva D et al. Primary radiotherapy in progressive optic nerve sheath meningiomas: a long-term follow-up study. Br. J. Ophthalmol.94(5), 564–568 (2010).
- Romanelli P, Wowra B, Muacevic A. Multisession cyberknife radiosurgery for optic nerve sheath meningiomas. Neurosurg. Focus23(6), E11 (2007).